Investigation summary: with a review of the available information, there is no evidence of a device malfunction or performance issues that would impact the reported events.Possible clinical factors that may have contributed to this event include the patients pre-existing history and related comorbidities, the progression of their underlying disease, issues related to the therapeutic use of anticoagulants, antiplatelet medications and the patient's complex post-operative course.There are possible patient, pharmacological and procedural factors that may have contributed to this event.This device is used for treatment, not diagnosis.The syncardia 70cc temporary total artificial heart (tah-t) is an implantable pulsatile biventricular replacement device that replaces a patient's native ventricles and valves and pumps blood to both the pulmonary and systemic circulation systems.The syncardia 70cc tah-t is indicated for use as a bridge to transplantation in cardiac transplant-eligible candidates at risk of imminent death from biventricular failure.The syncardia tah-t system is intended for use inside and outside the hospital.This event was assessed and is being reported as part of a retrospective review of events in response to an update to the mdr complaint sources.If new or additional information is received in the future, syncardia will file a follow-up mdr.(b)(4).
|
A retrospective review of intermacs de-identified data collected between (b)(6), 2015 and (b)(6), 2017 revealed that a patient expired with a cause of death listed as withdrawal of support.The intermacs data listed that is it unknown if the tah-t functioned normally.The intermacs data listed that the tah-t was not explanted.
|
While supported by the tah-t for 71 days, the patient experienced the following adverse events as defined by intermacs: at 0 day post implant - bleeding; 0 day post implant - other sae; 2 days post implant - infection/location: positive blood cultures, pulmonary/type: bacterial; 3 days post implant - infection/location: pulmonary/type: fungal; 13 days post implant - neurological dysfunction - cva/location: left hemisphere: frontal/severity: altered mental status; 13 days post implant - respiratory failure; 26 days post implant - renal dysfunction; 69 days post implant - hepatic dysfunction.
|